New to Pink Sheet?
Start a free trial today!
Register for our free email digests:
Register for our free email digests:
Brought to you by 
J&J, Vanderbilt U. partner in schizophrenia
Jan 2009
Executive Summary
In a three-year collaboration, Johnson & Johnson's Janssen Pharmaceutica NV unit will partner with Vanderbilt University to discover and develop new schizophrenia drugs. Vanderbilt will receive an up-front payment and committed research funding totaling $10mm, plus sales royalties, and reportedly could also get up to $100mm more in research milestones.
Deal Industry
-
Biotechnology
- Drug Discovery Tools
- Pharmacogenetics-Pharmacogenomics
- Pharmaceuticals
Deal Status
- Final
Deal Type
-
Alliance
- R+D and Marketing-Licensing
Already a Strategic Transactions subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
J&J, Vanderbilt U. partner in schizophrenia
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice